Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

被引：97
|
作者：
Aalders, Kim C. [1 ]
Tryfonidis, Konstantinos [1 ]
Senkus, Elbieta [2 ]
Cardoso, Fatima [3 ]
机构：
[1] European Org Res Treatment Canc, Dept Med, Brussels, Belgium
[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[3] Champalimaud Canc Ctr, Breast Unit, Lisbon, Portugal
来源：
CANCER TREATMENT REVIEWS | 2017年 / 53卷
关键词：
Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab; ENDOTHELIAL GROWTH-FACTOR; PHASE-III TRIAL; TYROSINE KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BEVACIZUMAB PLUS PACLITAXEL; OPEN-LABEL; 1ST-LINE TREATMENT; NEOADJUVANT CHEMOTHERAPY; TUMOR-CELLS; FACTOR VEGF;
D O I：
10.1016/j.ctrv.2016.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：98 / 110
页数：13
相关论文
共 50 条
  • [31] The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives
    Calvetti, Lorenzo
    Pilotto, Sara
    Carbognin, Luisa
    Ferrara, Roberto
    Caccese, Mario
    Tortora, Giampaolo
    Bria, Emilio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (09) : 1359 - 1370
  • [32] Vaccination approach to anti-angiogenic treatment of cancer
    Wentink, Madelon Q.
    Huijbers, Elisabeth J. M.
    de Gruijl, Tanja D.
    Verheul, Henk M. W.
    Olsson, Anna-Karin
    Griffioen, Arjan W.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2015, 1855 (02): : 155 - 171
  • [33] Combined anti-proliferative and anti-angiogenic strategies for cancer
    Bar, Jair
    Onn, Amir
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (05) : 701 - 715
  • [34] Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
    Tugues, Sonia
    Koch, Sina
    Gualandi, Laura
    Li, Xiujuan
    Claesson-Welsh, Lena
    MOLECULAR ASPECTS OF MEDICINE, 2011, 32 (02) : 88 - 111
  • [35] Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer
    Bell, Richard
    Cameron, David
    EJC SUPPLEMENTS, 2008, 6 (06): : 1 - 6
  • [36] Anti-angiogenic agents in the treatment of lung cancer: Indications and toxicities
    Clement-Duchene, C.
    Godbert, B.
    Martinet, V.
    REVUE DES MALADIES RESPIRATOIRES, 2012, 29 (02) : 161 - 177
  • [37] An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors
    Agrafiotis, Apostolos C.
    Berzenji, Lawek
    Koyen, Stien
    Vermeulen, Dries
    Winthagen, Rachel
    Hendriks, Jeroen M. H.
    Van Schil, Paul E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
  • [38] Current status and future directions of anti-angiogenic therapy for gliomas
    Wick, Wolfgang
    Platten, Michael
    Wick, Antje
    Hertenstein, Anne
    Radbruch, Alexander
    Bendszus, Martin
    Winkler, Frank
    NEURO-ONCOLOGY, 2016, 18 (03) : 315 - 328
  • [39] Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
    Lopes-Coelho, Filipa
    Martins, Filipa
    Pereira, Sofia A.
    Serpa, Jacinta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (07)
  • [40] Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
    Mackey, John R.
    Kerbel, Robert S.
    Gelmon, Karen A.
    McLeod, Deanna M.
    Chia, Stephen K.
    Rayson, Daniel
    Verma, Sunil
    Collins, Loretta L.
    Paterson, Alexander H. G.
    Robidoux, Andre
    Pritchard, Kathleen I.
    CANCER TREATMENT REVIEWS, 2012, 38 (06) : 673 - 688
12345